Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Prostate tumours with β-catenin activation relied on the non-canonical WNT ligand WNT5a for sustained growth.
|
31719098 |
2020 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
MMP7 disrupted E-cadherin/β-catenin complex to upregulate EMT transcription factors in mouse prostate tumors.
|
27375020 |
2017 |
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We found that expression of the ALDH1A1 gene is regulated by the WNT signaling pathway and co-occurs with expression of β-catenin in prostate tumor specimens.
|
25670168 |
2015 |
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone.
|
18008331 |
2008 |
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Alterations in beta-catenin expression and localization in prostate cancer.
|
18459111 |
2008 |
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Although beta-catenin stability is regulated by a multicomponent destruction complex, mutational alterations of beta-catenin or other components of the destruction complexes are rare in prostate tumors.
|
18819930 |
2008 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Beta-catenin mediates alteration in cell proliferation, motility and invasion of prostate cancer cells by differential expression of E-cadherin and protein kinase D1.
|
17979146 |
2008 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
Prostate tumors induced by the deletion of Apc have elevated levels of beta-catenin protein and are highly proliferative.
|
17363566 |
2007 |
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Does the inhibition of c-myc expression mediate the anti-tumor activity of PPAR's ligands in prostate cancer cell lines?
|
17466258 |
2007 |
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction.
|
16428447 |
2006 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
Positive inter-regulation between beta-catenin/T cell factor-4 signaling and endothelin-1 signaling potentiates proliferation and survival of prostate cancer cells.
|
16291872 |
2006 |
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
LHGDN |
Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.
|
15455387 |
2005 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
LHGDN |
It was previously shown that 5% of prostate tumors harbor CTNNB1 mutations, suggesting that this tumor type may involve a deregulated APC/CTNNB1 pathway.
|
11921277 |
2002 |
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
It was previously shown that 5% of prostate tumors harbor CTNNB1 mutations, suggesting that this tumor type may involve a deregulated APC/CTNNB1 pathway.
|
11921277 |
2002 |
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
MGD |
|
|
|